康哲藥業(00867.HK)建議於新加坡交易所作第二上市
格隆匯6月24日丨康哲藥業(00867.HK)公吿,公司建議將其普通股以介紹方式於新加坡證券交易所有限公司("新交所")作第二上市。建議第二上市(倘落實進行)將不涉及增發新股,其後股份將繼續於香港聯合交易所有限公司作主要上市及買賣。
於2025年6月24日,公司接獲中國證券監督管理委員會就建議第二上市發出境外發行上市備案通知書。
董事相信,完成建議第二上市後,將使公司能夠進入新加坡證券市場。預期此舉將加強本集團於該市場地位,並提升公司的全球知名度,從而助力國際業務拓展。儘管建議第二上市不會涉及在新加坡進行任何股權籌資,惟本公司預計建議第二上市將擴闊其股東基礎,及開闢未來額外籌資渠道。長遠而言,預期這將推廣公司企業形象及提升其證券流動性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.